Compare Amgen, Inc. (AMGN) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Monster Beverage Corp — how do they compare? Amgen, Inc. trades at $356.4 (market cap $196.12B), while Monster Beverage Corp trades at $97.05 (market cap $95.25B). The key difference: Amgen, Inc. is far larger — about 2.1× Monster Beverage Corp's market cap, and Amgen, Inc. pays a 2.77% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals.
| AMGN | MNST | |
|---|---|---|
Market Cap | $196.12B | $95.25B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $97.64 |
52-Week Low | $271.18 | $58.65 |
Enterprise Value | $241.41B | $93.54B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Monster Beverage (MNST) trades at $97.39, up 0.87% today, showing strong momentum after recent earnings beats. The stock exhibits a bullish technical trend, with moving averages supporting further upside, while oscillators are neutral. Fundamentally, the company reported robust revenue growth to $8.29 billion in 2025, with a net income margin of 23.11%, and announced a 2-for-1 stock split effective August 2026, reflecting confidence in future performance.
The outlook remains positive given consistent earnings outperformance and international expansion, but high valuation multiples like a P/E of 47.05 pose risks if growth slows. Investor sentiment is buoyed by analyst consensus favoring buys, though competitive pressures and macroeconomic factors warrant caution for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
